Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for head and neck cancer: drug may prevent recurrence after chemoradiation

NCT ID NCT06256588

Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug dostarlimab, given after standard chemoradiation, can help prevent head and neck cancer from coming back or spreading. About 864 adults with advanced but not surgically removable head and neck cancer will receive either dostarlimab or a placebo. The main goal is to see if dostarlimab improves the time patients stay cancer-free.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 864 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply: * Has newly diagnosed unresected Locally Advanced (LA) histologically confirmed HNSCC of the oral cavity, oropharynx, hypopharynx or larynx and completed cisplatin plus radiotherapy (termed "CRT" in this protocol) with curative intent and has no evidence of distant metastatic disease. * Has provided acceptable core or excisional biopsy obtained prior to CRT: * PD-L1 positive tumor status * If the primary tumor site is oropharyngeal carcinoma, the participant must have p16 immunohistochemistry (IHC) testing. * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Has adequate organ function. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: * Has received prior radiation therapy (RT), systemic therapy, targeted therapy, or surgery for management of head and neck cancer not considered part of CRT. Participants receiving induction chemotherapy are excluded. CRT combinations with components other than cisplatin and RT (e.g., experimental agents, including radiosensitizers/radioprotectants, cetuximab) are not eligible. * Has cancer outside of the oropharynx, larynx, hypopharynx or oral cavity, such as nasopharyngeal, sinus, other para-nasal, or other unknown primary head and neck cancer. Has more than one primary HNSCC tumor. * Has experienced any of the following with prior immunotherapy: any immune-related adverse event (irAE) of Grade ≥3, immune-related severe neurologic events of any grade (e.g., myasthenic syndrome/myasthenia gravis, encephalitis, Guillain-Barré Syndrome, or transverse myelitis), exfoliative dermatitis of any grade (Stevens-Johnson Syndrome, toxic epidermal necrolysis, or Drug Rash with Eosinophilia and Systemic Symptoms \[DRESS\] syndrome), or myocarditis of any grade. Non-clinically significant laboratory abnormalities are not exclusionary. * Has undergone any major surgical procedure or experienced significant traumatic injury that has not resolved by the time of randomization. * Has any history of interstitial lung disease or pneumonitis (past or current). * Has cirrhosis of any stage or current unstable liver biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice. * Has a history or current evidence of any medical condition, therapy, or laboratory abnormality that might confound the study results, interfere with their participation for the full duration of the study intervention, or indicate it is not in the best interest of the participant to participate, in the opinion of the investigator. * Is receiving any other anticancer or experimental therapy. No other experimental therapies (including but not limited to chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, or other experimental drugs) of any kind are permitted while the participant is receiving study intervention. * Previous treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or an agent directed to another stimulatory or coinhibitory T-cell receptor \[e.g., Cytotoxic T-lymphocyte associated protein 4 (CTLA4), OX-40, CD137\] * Is pregnant, breastfeeding, or expecting to conceive children within the projected duration of the study, starting with the Screening Visit through 120 days after the last dose of study intervention. * Has a history of severe allergic and/or anaphylactic reactions to chimeric, human or humanized antibodies, fusion proteins, or known allergies to dostarlimab or its excipients.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced unresected head and neck squamous cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

head and neck neoplasm Head and Neck Neoplasms head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neoplasms, head and neck

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    256 sites in 31 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • GSK Investigational Site

    RECRUITING

    Jonesboro, Arkansas, 72401, United States

  • GSK Investigational Site

    RECRUITING

    Los Angeles, California, 90095, United States

  • GSK Investigational Site

    RECRUITING

    Solvang, California, 93463, United States

  • GSK Investigational Site

    RECRUITING

    Stockton, California, 95204, United States

  • GSK Investigational Site

    RECRUITING

    Torrance, California, 90505, United States

  • GSK Investigational Site

    RECRUITING

    Farmington, Connecticut, 06030-1628, United States

  • GSK Investigational Site

    RECRUITING

    New Haven, Connecticut, 06520, United States

  • GSK Investigational Site

    RECRUITING

    Washington D.C., District of Columbia, 20010, United States

  • GSK Investigational Site

    RECRUITING

    St. Petersburg, Florida, 33709, United States

  • GSK Investigational Site

    WITHDRAWN

    Tamarac, Florida, 33321, United States

  • GSK Investigational Site

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • GSK Investigational Site

    RECRUITING

    Fort Wayne, Indiana, 46804, United States

  • GSK Investigational Site

    RECRUITING

    Iowa City, Iowa, 52242, United States

  • GSK Investigational Site

    RECRUITING

    Lexington, Kentucky, 40536, United States

  • GSK Investigational Site

    RECRUITING

    Columbia, Maryland, 21044, United States

  • GSK Investigational Site

    RECRUITING

    Worcester, Massachusetts, 01655-0002, United States

  • GSK Investigational Site

    RECRUITING

    St Louis, Missouri, 63110, United States

  • GSK Investigational Site

    RECRUITING

    Omaha, Nebraska, 68114, United States

  • GSK Investigational Site

    COMPLETED

    New York, New York, 10032, United States

  • GSK Investigational Site

    RECRUITING

    The Bronx, New York, 10468, United States

  • GSK Investigational Site

    RECRUITING

    Canton, Ohio, 44718, United States

  • GSK Investigational Site

    COMPLETED

    Cincinnati, Ohio, 45219, United States

  • GSK Investigational Site

    RECRUITING

    Tulsa, Oklahoma, 74146, United States

  • GSK Investigational Site

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

  • GSK Investigational Site

    RECRUITING

    Pittsburgh, Pennsylvania, 15212, United States

  • GSK Investigational Site

    RECRUITING

    Charleston, South Carolina, 29425, United States

  • GSK Investigational Site

    COMPLETED

    Greenville, South Carolina, 29607, United States

  • GSK Investigational Site

    RECRUITING

    Chattanooga, Tennessee, 37404, United States

  • GSK Investigational Site

    RECRUITING

    Germantown, Tennessee, 38138, United States

  • GSK Investigational Site

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • GSK Investigational Site

    RECRUITING

    Dallas, Texas, 75246, United States

  • GSK Investigational Site

    RECRUITING

    Fort Worth, Texas, 76104, United States

  • GSK Investigational Site

    RECRUITING

    San Antonio, Texas, 78217, United States

  • GSK Investigational Site

    RECRUITING

    Fredericksburg, Virginia, 22408, United States

  • GSK Investigational Site

    RECRUITING

    Wytheville, Virginia, 24382, United States

  • GSK Investigational Site

    WITHDRAWN

    Tacoma, Washington, 98405, United States

  • GSK Investigational Site

    RECRUITING

    Buenos Aires, 1023, Argentina

  • GSK Investigational Site

    RECRUITING

    Buenos Aires, C1425, Argentina

  • GSK Investigational Site

    RECRUITING

    Buenos Aires, C1437GZT, Argentina

  • GSK Investigational Site

    RECRUITING

    Ciudad Autonoma de Buenos Aire, C1426, Argentina

  • GSK Investigational Site

    RECRUITING

    Córdoba, 5000, Argentina

  • GSK Investigational Site

    RECRUITING

    Florida, 1602, Argentina

  • GSK Investigational Site

    RECRUITING

    Rosario, S2002, Argentina

  • GSK Investigational Site

    RECRUITING

    San Juan, J5400, Argentina

  • GSK Investigational Site

    RECRUITING

    San Miguel de Tucumán, T4000GTB, Argentina

  • GSK Investigational Site

    RECRUITING

    Viedma, R8500ACE, Argentina

  • GSK Investigational Site

    RECRUITING

    Blacktown, New South Wales, 2148, Australia

  • GSK Investigational Site

    RECRUITING

    Douglas, Queensland, 4814, Australia

  • GSK Investigational Site

    WITHDRAWN

    Herston, Queensland, 4029, Australia

  • GSK Investigational Site

    RECRUITING

    Ballarat, Victoria, 3350, Australia

  • GSK Investigational Site

    RECRUITING

    Geelong, Victoria, 3220, Australia

  • GSK Investigational Site

    COMPLETED

    Melbourne, Victoria, 3004, Australia

  • GSK Investigational Site

    RECRUITING

    Brussels, 1200, Belgium

  • GSK Investigational Site

    RECRUITING

    Charleroi, 6060, Belgium

  • GSK Investigational Site

    RECRUITING

    Edegem, 2650, Belgium

  • GSK Investigational Site

    RECRUITING

    Ghent, 9000, Belgium

  • GSK Investigational Site

    RECRUITING

    Liège, 4000, Belgium

  • GSK Investigational Site

    RECRUITING

    Yvoir, 5530, Belgium

  • GSK Investigational Site

    RECRUITING

    Barretos, 14784-400, Brazil

  • GSK Investigational Site

    RECRUITING

    Belo Horizonte, 30110-022, Brazil

  • GSK Investigational Site

    RECRUITING

    Florianópolis, 88020-210, Brazil

  • GSK Investigational Site

    RECRUITING

    Ijuí, 98700-000, Brazil

  • GSK Investigational Site

    RECRUITING

    Jaú, 17210-120, Brazil

  • GSK Investigational Site

    RECRUITING

    Joinville, 89201-260, Brazil

  • GSK Investigational Site

    RECRUITING

    Natal, 59075-740, Brazil

  • GSK Investigational Site

    RECRUITING

    Porto Alegre, 90610-000, Brazil

  • GSK Investigational Site

    RECRUITING

    Salvador, 41253-190, Brazil

  • GSK Investigational Site

    RECRUITING

    Salvador, 41950-640, Brazil

  • GSK Investigational Site

    RECRUITING

    São José do Rio Preto, 15090-200, Brazil

  • GSK Investigational Site

    RECRUITING

    São Paulo, 01246-000, Brazil

  • GSK Investigational Site

    RECRUITING

    Vitória, 29043-260, Brazil

  • GSK Investigational Site

    RECRUITING

    Greater Sudbury, Ontario, P3E 5J1, Canada

  • GSK Investigational Site

    RECRUITING

    Hamilton, Ontario, L8V 5C2, Canada

  • GSK Investigational Site

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • GSK Investigational Site

    COMPLETED

    Montreal, Quebec, H3T 1E2, Canada

  • GSK Investigational Site

    RECRUITING

    Chongqing, Chongqing Municipality, 400030, China

  • GSK Investigational Site

    RECRUITING

    Baoding, Hebei, 071000, China

  • GSK Investigational Site

    RECRUITING

    Nanyang, Henan, 473005, China

  • GSK Investigational Site

    RECRUITING

    Beijing, 100036, China

  • GSK Investigational Site

    RECRUITING

    Changsha, 410013, China

  • GSK Investigational Site

    RECRUITING

    Changzhou, 213032, China

  • GSK Investigational Site

    RECRUITING

    Chengdu, 610000, China

  • GSK Investigational Site

    RECRUITING

    Chengdu, 610041, China

  • GSK Investigational Site

    RECRUITING

    Dongguan, 523059, China

  • GSK Investigational Site

    RECRUITING

    Fuzhou, 350005, China

  • GSK Investigational Site

    ACTIVE_NOT_RECRUITING

    Fuzhou, 350014, China

  • GSK Investigational Site

    RECRUITING

    Guangzhou, 510120, China

  • GSK Investigational Site

    RECRUITING

    Guangzhou, 510503, China

  • GSK Investigational Site

    RECRUITING

    Hangzhou, 310003, China

  • GSK Investigational Site

    RECRUITING

    Hangzhou, 310022, China

  • GSK Investigational Site

    RECRUITING

    Hefei, 230001, China

  • GSK Investigational Site

    RECRUITING

    Hengyang, 421000, China

  • GSK Investigational Site

    RECRUITING

    Jinan, 250117, China

  • GSK Investigational Site

    RECRUITING

    Kunming, 650106, China

  • GSK Investigational Site

    ACTIVE_NOT_RECRUITING

    Lanzhou, 730030, China

  • GSK Investigational Site

    RECRUITING

    Linyi, 276002, China

  • GSK Investigational Site

    RECRUITING

    Nanchang, 330006, China

  • GSK Investigational Site

    RECRUITING

    Nanchang, 330029, China

  • GSK Investigational Site

    RECRUITING

    Nanning, 530021, China

  • GSK Investigational Site

    RECRUITING

    Shanghai, 200032, China

  • GSK Investigational Site

    RECRUITING

    Taiyuan, 030013, China

  • GSK Investigational Site

    RECRUITING

    Wuhan, 430030, China

  • GSK Investigational Site

    RECRUITING

    Wuhan, 430079, China

  • GSK Investigational Site

    RECRUITING

    Xiamen, 361004, China

  • GSK Investigational Site

    RECRUITING

    Xuzhou, 221004, China

  • GSK Investigational Site

    RECRUITING

    Zhengzhou, 450052, China

  • GSK Investigational Site

    RECRUITING

    Zhuhai, 519001, China

  • GSK Investigational Site

    WITHDRAWN

    Olomouc, 779 00, Czechia

  • GSK Investigational Site

    RECRUITING

    Prague, 10034, Czechia

  • GSK Investigational Site

    RECRUITING

    Prague, 150 08, Czechia

  • GSK Investigational Site

    RECRUITING

    Prague, 180 81, Czechia

  • GSK Investigational Site

    RECRUITING

    Zlín, 76275, Czechia

  • GSK Investigational Site

    RECRUITING

    Ars-Laquenexy, 57530, France

  • GSK Investigational Site

    RECRUITING

    Caen, 14075, France

  • GSK Investigational Site

    RECRUITING

    Dijon, 21079, France

  • GSK Investigational Site

    RECRUITING

    Marseille, 13005, France

  • GSK Investigational Site

    RECRUITING

    Poitiers, 86021, France

  • GSK Investigational Site

    RECRUITING

    Quimper, 29000, France

  • GSK Investigational Site

    RECRUITING

    Rennes, 35042, France

  • GSK Investigational Site

    RECRUITING

    Rouen, 76038, France

  • GSK Investigational Site

    COMPLETED

    Vandœuvre-lès-Nancy, 54519, France

  • GSK Investigational Site

    RECRUITING

    Augsburg, 86156, Germany

  • GSK Investigational Site

    RECRUITING

    Berlin, 12351, Germany

  • GSK Investigational Site

    RECRUITING

    Berlin, 13353, Germany

  • GSK Investigational Site

    RECRUITING

    Erlangen, 91054, Germany

  • GSK Investigational Site

    RECRUITING

    Essen, 45147, Germany

  • GSK Investigational Site

    RECRUITING

    Giessen, 35392, Germany

  • GSK Investigational Site

    RECRUITING

    Hamburg, 22087, Germany

  • GSK Investigational Site

    WITHDRAWN

    Neuruppin, 16816, Germany

  • GSK Investigational Site

    RECRUITING

    Straubing, 94315, Germany

  • GSK Investigational Site

    RECRUITING

    Athens, 115 22, Greece

  • GSK Investigational Site

    RECRUITING

    Athens, 12462, Greece

  • GSK Investigational Site

    RECRUITING

    Larissa, 41100, Greece

  • GSK Investigational Site

    RECRUITING

    Thessaloniki, 564 29, Greece

  • GSK Investigational Site

    RECRUITING

    Győr, 9023, Hungary

  • GSK Investigational Site

    RECRUITING

    Kaposvár, 7400, Hungary

  • GSK Investigational Site

    RECRUITING

    Nyíregyháza, H-4400, Hungary

  • GSK Investigational Site

    RECRUITING

    Mumbai, Maharashtra, 400071, India

  • GSK Investigational Site

    RECRUITING

    Pune, Maharashtra, 411001, India

  • GSK Investigational Site

    RECRUITING

    Bengaluru, 560066, India

  • GSK Investigational Site

    RECRUITING

    Bhubaneswar, 751019, India

  • GSK Investigational Site

    RECRUITING

    Gurgaon, 122001, India

  • GSK Investigational Site

    RECRUITING

    Hyderabad, 500004, India

  • GSK Investigational Site

    RECRUITING

    Mumbai, 400012, India

  • GSK Investigational Site

    RECRUITING

    Nashik, 422002, India

  • GSK Investigational Site

    RECRUITING

    Nehru Nagar Belagavi Karnataka 590010, 590010, India

  • GSK Investigational Site

    RECRUITING

    Surat, 395002, India

  • GSK Investigational Site

    RECRUITING

    Vijayawada, 520002, India

  • GSK Investigational Site

    RECRUITING

    Ashdod, 7747629, Israel

  • GSK Investigational Site

    RECRUITING

    Haifa, 3109601, Israel

  • GSK Investigational Site

    WITHDRAWN

    Jerusalem, 9112001, Israel

  • GSK Investigational Site

    RECRUITING

    Tel Aviv, 64239, Israel

  • GSK Investigational Site

    RECRUITING

    Bolzano, Prov. Aut. Bolzano-Alto Adige, 39100, Italy

  • GSK Investigational Site

    RECRUITING

    Bologna, 40139, Italy

  • GSK Investigational Site

    RECRUITING

    Milan, 20133, Italy

  • GSK Investigational Site

    RECRUITING

    Milan, 20141, Italy

  • GSK Investigational Site

    WITHDRAWN

    Naples, 80131, Italy

  • GSK Investigational Site

    RECRUITING

    Pavia, 27100, Italy

  • GSK Investigational Site

    RECRUITING

    Prato, 59100, Italy

  • GSK Investigational Site

    RECRUITING

    Roma, 00161, Italy

  • GSK Investigational Site

    RECRUITING

    Roma, 00168, Italy

  • GSK Investigational Site

    RECRUITING

    Rozzano MI, 20089, Italy

  • GSK Investigational Site

    RECRUITING

    Savona, 17100, Italy

  • GSK Investigational Site

    RECRUITING

    Aichi, 464-8681, Japan

  • GSK Investigational Site

    RECRUITING

    Aomori, 036-8563, Japan

  • GSK Investigational Site

    RECRUITING

    Chiba, 260-8717, Japan

  • GSK Investigational Site

    RECRUITING

    Chiba, 277-8577, Japan

  • GSK Investigational Site

    RECRUITING

    Ehime, 791-0280, Japan

  • GSK Investigational Site

    RECRUITING

    Fukuoka, 812-8582, Japan

  • GSK Investigational Site

    RECRUITING

    Gunma, 371-8511, Japan

  • GSK Investigational Site

    RECRUITING

    Hokkaido, 060-8648, Japan

  • GSK Investigational Site

    RECRUITING

    Hyōgo, 650-0017, Japan

  • GSK Investigational Site

    RECRUITING

    Hyōgo, 673-8558, Japan

  • GSK Investigational Site

    RECRUITING

    Kagoshima, 890-8520, Japan

  • GSK Investigational Site

    RECRUITING

    Kanagawa, 236-0004, Japan

  • GSK Investigational Site

    RECRUITING

    Kanagawa, 252-0375, Japan

  • GSK Investigational Site

    RECRUITING

    Kanagawa, 259-1193, Japan

  • GSK Investigational Site

    RECRUITING

    Kyoto, 612-8555, Japan

  • GSK Investigational Site

    RECRUITING

    Miyagi, 981-1293, Japan

  • GSK Investigational Site

    COMPLETED

    Niigata, 951-8520, Japan

  • GSK Investigational Site

    COMPLETED

    Numakunai, 028-3695, Japan

  • GSK Investigational Site

    ACTIVE_NOT_RECRUITING

    Okinawa, 901-2725, Japan

  • GSK Investigational Site

    RECRUITING

    Osaka, 541-8567, Japan

  • GSK Investigational Site

    RECRUITING

    Saitama, 350-1298, Japan

  • GSK Investigational Site

    RECRUITING

    Shizuoka, 411-8777, Japan

  • GSK Investigational Site

    RECRUITING

    Tokyo, 105-8471, Japan

  • GSK Investigational Site

    RECRUITING

    Tokyo, 113-8519, Japan

  • GSK Investigational Site

    RECRUITING

    Tokyo, 152-8902, Japan

  • GSK Investigational Site

    RECRUITING

    Tokyo, 160-0023, Japan

  • GSK Investigational Site

    RECRUITING

    Tottori, 683-8504, Japan

  • GSK Investigational Site

    RECRUITING

    Guadajalara, 44280, Mexico

  • GSK Investigational Site

    RECRUITING

    Guadalajara, 44650, Mexico

  • GSK Investigational Site

    RECRUITING

    Mexico City, 06760, Mexico

  • GSK Investigational Site

    RECRUITING

    Mexico City, 11510, Mexico

  • GSK Investigational Site

    RECRUITING

    Monterrey, 66260, Mexico

  • GSK Investigational Site

    RECRUITING

    Oaxaca City, 68020, Mexico

  • GSK Investigational Site

    RECRUITING

    Bergen, 5021, Norway

  • GSK Investigational Site

    RECRUITING

    Oslo, 0379, Norway

  • GSK Investigational Site

    RECRUITING

    Troms, 9038, Norway

  • GSK Investigational Site

    RECRUITING

    Bielsko-Biala, 43-300, Poland

  • GSK Investigational Site

    RECRUITING

    Gliwice, 44-102, Poland

  • GSK Investigational Site

    RECRUITING

    Katowice, 40-514, Poland

  • GSK Investigational Site

    RECRUITING

    Olsztyn, 10-228, Poland

  • GSK Investigational Site

    RECRUITING

    Przemyśl, 37-700, Poland

  • GSK Investigational Site

    RECRUITING

    Siedlce, 08-110, Poland

  • GSK Investigational Site

    RECRUITING

    Warsaw, 04-141, Poland

  • GSK Investigational Site

    RECRUITING

    Coimbra, 3000-075, Portugal

  • GSK Investigational Site

    RECRUITING

    Faro, 8000-386, Portugal

  • GSK Investigational Site

    RECRUITING

    Lisbon, 1649-035, Portugal

  • GSK Investigational Site

    RECRUITING

    Lisbon, 1998-018, Portugal

  • GSK Investigational Site

    RECRUITING

    Matosinhos Municipality, 4464-509, Portugal

  • GSK Investigational Site

    RECRUITING

    Porto, 4200-072, Portugal

  • GSK Investigational Site

    RECRUITING

    Porto, 4200-319, Portugal

  • GSK Investigational Site

    RECRUITING

    Vila Nova de Gaia, 4434-502, Portugal

  • GSK Investigational Site

    RECRUITING

    Bucharest, 013823, Romania

  • GSK Investigational Site

    RECRUITING

    Bucharest, 020142, Romania

  • GSK Investigational Site

    RECRUITING

    Craiova, 200508, Romania

  • GSK Investigational Site

    RECRUITING

    Craiova, 200542, Romania

  • GSK Investigational Site

    WITHDRAWN

    Floreşti, 407280, Romania

  • GSK Investigational Site

    RECRUITING

    Iași, 700483, Romania

  • GSK Investigational Site

    RECRUITING

    Oradea, 410469, Romania

  • GSK Investigational Site

    RECRUITING

    Piteşti, 110283, Romania

  • GSK Investigational Site

    RECRUITING

    Suceava, 720214, Romania

  • GSK Investigational Site

    RECRUITING

    Timișoara, 300239, Romania

  • GSK Investigational Site

    RECRUITING

    Riyadh, 12372, Saudi Arabia

  • GSK Investigational Site

    RECRUITING

    Riyadh, Saudi Arabia

  • GSK Investigational Site

    RECRUITING

    Singapore, 168583, Singapore

  • GSK Investigational Site

    RECRUITING

    Singapore, 308433, Singapore

  • GSK Investigational Site

    RECRUITING

    Busan, 602-030, South Korea

  • GSK Investigational Site

    WITHDRAWN

    Pusan, 49241, South Korea

  • GSK Investigational Site

    RECRUITING

    Seoul, 03722, South Korea

  • GSK Investigational Site

    RECRUITING

    Seoul, 06351, South Korea

  • GSK Investigational Site

    RECRUITING

    Seoul, 110 744, South Korea

  • GSK Investigational Site

    RECRUITING

    Suwon Gyeonggi-do, 16247, South Korea

  • GSK Investigational Site

    RECRUITING

    BaracaldoVizcaya, 48903, Spain

  • GSK Investigational Site

    RECRUITING

    Barcelona, 08023, Spain

  • GSK Investigational Site

    RECRUITING

    Cartagena Murcia, 30202, Spain

  • GSK Investigational Site

    RECRUITING

    HebrOn, 08035, Spain

  • GSK Investigational Site

    RECRUITING

    Jerez de la Frontera, 11407, Spain

  • GSK Investigational Site

    RECRUITING

    L'Hospitalet de Llobrega, 08908, Spain

  • GSK Investigational Site

    RECRUITING

    Lugo, 27003, Spain

  • GSK Investigational Site

    RECRUITING

    Madrid, 28040, Spain

  • GSK Investigational Site

    RECRUITING

    Madrid, 28041, Spain

  • GSK Investigational Site

    RECRUITING

    Madrid, 28046, Spain

  • GSK Investigational Site

    RECRUITING

    Pamplona, 31008, Spain

  • GSK Investigational Site

    RECRUITING

    Salamanca, 37007, Spain

  • GSK Investigational Site

    RECRUITING

    Santander, 39008, Spain

  • GSK Investigational Site

    RECRUITING

    Zaragoza, 50009, Spain

  • GSK Investigational Site

    RECRUITING

    Gothenburg, SE-413 45, Sweden

  • GSK Investigational Site

    RECRUITING

    Stockholm, SE-171 64, Sweden

  • GSK Investigational Site

    RECRUITING

    Uppsala, SE-751 85, Sweden

  • GSK Investigational Site

    RECRUITING

    Basel, 4031, Switzerland

  • GSK Investigational Site

    RECRUITING

    Fribourg, 1708, Switzerland

  • GSK Investigational Site

    RECRUITING

    Geneva, 1211, Switzerland

  • GSK Investigational Site

    RECRUITING

    Lausanne, 1011, Switzerland

  • GSK Investigational Site

    RECRUITING

    Zurich, 8091, Switzerland

  • GSK Investigational Site

    RECRUITING

    Changhua, 500, Taiwan

  • GSK Investigational Site

    RECRUITING

    Kaohsiung City, 833, Taiwan

  • GSK Investigational Site

    RECRUITING

    Taichung, 40447, Taiwan

  • GSK Investigational Site

    RECRUITING

    Taipei, 100, Taiwan

  • GSK Investigational Site

    RECRUITING

    Adapazarı, Turkey (Türkiye)

  • GSK Investigational Site

    RECRUITING

    Ankara, 06010, Turkey (Türkiye)

  • GSK Investigational Site

    RECRUITING

    Ankara, 06100, Turkey (Türkiye)

  • GSK Investigational Site

    RECRUITING

    Ankara, 06520, Turkey (Türkiye)

  • GSK Investigational Site

    RECRUITING

    Antalya, 7050, Turkey (Türkiye)

  • GSK Investigational Site

    RECRUITING

    Istanbul, 34010, Turkey (Türkiye)

  • GSK Investigational Site

    RECRUITING

    Istanbul, 34662, Turkey (Türkiye)

  • GSK Investigational Site

    RECRUITING

    Istanbul, Şişli, 34384, Turkey (Türkiye)

  • GSK Investigational Site

    RECRUITING

    Abu Dhabi, United Arab Emirates

  • GSK Investigational Site

    RECRUITING

    Al Ain City, United Arab Emirates

  • GSK Investigational Site

    RECRUITING

    Dubai, United Arab Emirates

  • GSK Investigational Site

    RECRUITING

    Edinburgh, EH4 2XU, United Kingdom

  • GSK Investigational Site

    RECRUITING

    Gloucester, GL1 3NN, United Kingdom

  • GSK Investigational Site

    RECRUITING

    London, SW3 6JJ, United Kingdom

  • GSK Investigational Site

    RECRUITING

    Nottingham, NG5 1PB, United Kingdom

  • GSK Investigational Site

    RECRUITING

    Sutton, SM2 5PT, United Kingdom

  • GSK Investigational Site

    WITHDRAWN

    Wolverhampton, WV10 0QP, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.